Welcome to the SheSpeaks #beBRCAware Program. Thank you for joining us to raise awareness of the BRCA gene and the role it plays in ovarian cancer. We look forward to reading your blog post!
How to Participate in the Program
- Blog About It: Write a blog post by Monday, March 23 to spread the word about the #beBRCAware campaign. Your blog post should:
- Use the key messages provided to empower others to #beBRCAware.
- Share your personal connection to this cause or explain why this initiative is important to you.
- Include the following disclosure statement: I received $150 from AstraZeneca, and any opinions expressed by me are honest and reflect my actual experience. This is a sponsored post for SheSpeaks/AstraZeneca.
- Encourage your readers to share with their networks about the BRCA gene and the role it plays in ovarian cancer and share support for women battling ovarian cancer by using the hashtag #beBRCAware.
- Share It: Use the hashtag #beBRCAware to help spread the word on your social channels. Share your blog post on Facebook and Twitter using the hashtag #beBRCAware and be sure to loop in @beBRCAware and @SheSpeaksUp.
- The following must be avoided in posts:
- Any product/drug-specific information or comparison. This must be an unbranded post, so there must be no mention of products.
- Adverse events. This post must not address any specific products/drugs - as such, there must not be any discussion of adverse events.
- Medical advice. This post can address common misperceptions about BRCA testing and should recommend communicating with the treatment team for specific treatment options. As such, no specific medical advice should be given.
- Endorsements. While the post is intended to provide useful information to the ovarian cancer community, this should not be a forum for endorsements of specific physicians, medical centers, or treatment therapies.
Important Campaign Links
Key Messages & Calls to Action for Your #beBRCAware Blog Post
What is a BRCA gene?
BRCA1 and BRCA2 are human genes involved with cell growth, cell division, and cell repair. Although they are most commonly associated with BReast CAncer, approximately 15% of women with ovarian cancer also have BRCA gene mutations.1,2
Who should get tested for the BRCA gene?
Clinical practice guidelines recommend that all women with epithelial ovarian cancer be considered for BRCA testing3. The test is simple and easy. A blood or saliva sample can be taken at your physician’s office or at a local lab. Medicare, Medicaid, and most private insurance carriers cover BRCA testing for women with a diagnosis of ovarian cancer. Certain mutations in BRCA1 or BRCA2 can affect how you and your physician choose to manage ovarian cancer.
Important BRCA Facts:
- Women with BRCA gene mutations have an increased risk of developing ovarian cancer.4
- In the general population, 1.4 percent4 of women will be diagnosed with ovarian cancer, while up to 40 percent of women with BRCA 1/2 mutations will be diagnosed with ovarian cancer in their lifetime.5
- An estimated 15% of ovarian cancers are linked to BRCA mutations.1,2
- BRCA gene mutations can play a key role in serous ovarian cancer, the most common form of ovarian cancer.6
- Nearly one half of women with ovarian cancer who are BRCA-positive have no significant family history of breast or ovarian cancer.7
How You and Your Blog Readers Can Help
- Raise Awareness. Help spread the word about the connection between the BRCA gene and ovarian cancer. Information is powerful and can affect the way cancer is treated. Share campaign information on your social networks with the hashtag #beBRCAware to let other women know the facts above, especially:
- Women with BRCA gene mutations have an increased risk of developing ovarian cancer4
- In the general population, 1.4 percent of women will be diagnosed with ovarian cancer4, while up to 40 percent of women with BRCA 1/2 mutations will be diagnosed with ovarian cancer in their lifetime5
- Nearly one half of women with ovarian cancer who are BRCA-positive have no significant family history of breast or ovarian cancer7
- Share Information. Do you know a woman diagnosed with or at risk for ovarian cancer? Share with your readers the website myocjourney.com, which provides information about diagnosis, BRCA gene testing, treatment plans, and support networks that may be helpful to these women now and can help alert more women to what they need to know about BRCA and ovarian cancer.
- Show Your Support. Encourage women battling ovarian cancer to stay positive by sharing some of the images below on your blog and social networks.
Images for Your Blog Post
Please feel free to use the images below in your blog post, and share them on your social media channels to inspire others to #beBRCAware. Click for full size images.
Submit Your Blog Post
Share your blog link with us by clicking the "submit your blog" button below and adding your blog post URL. Payment will be sent within three business days of completing the assignment and submitting your post.
1. Pal T, Permuth-Wey J, Betts JA, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer. 2005;104(12):2807-2816.
2. National Cancer Institute. BRCA1 and BRCA2: Cancer risk and genetic testing. http://www.cancer.gov/cancertopics/factsheet/Risk/BRCA. Accessed June 2, 2014.
3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Breast and Ovarian. Version 4;2013.2
4. National Cancer Institute. BRCA1 and BRCA 2: Cancer risk and genetic testing. http://www.cancer.gov/cancertopics/factsheet/Risk/BRCA. Last Accessed: October 30, 2014.
5. Petrucelli N, et al.,1998 Sep 4 [Updated 2013 Sep 26]. In: Pagon RA, Adam MP, Bird TD, et al., editors. GeneReviews [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2014.
6. Wang ZC, et al. Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome. Clin Cancer Res. 2012;18:5806-5815.
7. Song H., The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population. Human Molecular Genetics 2014;23(17):4703-4709.